Survival Time and Associated Factors Among Adults Living with HIV After Initiation of HAART in South Gondar, Northwest Ethiopia: A Retrospective Cohort

Overview

Journal J Multidiscip Healthc

Publisher Dove Medical Press

Specialty Health Services

Date 2021 Jun 25

PMID 34168459

Citations 5

Authors

Genzeb Deres

Zelalem Mehari Nigussie

Muluken Genetu Chanie

Nigusu Worku

Affiliations

Soon will be listed here.

Abstract

Background: Antiretroviral therapy consistently improves the survival of people living with HIV and contributes to preventing the development of new infections. Studies of antiretroviral therapy programs in Africa have shown a high mortality rate during the first 6 months after initiation of HAART in rural health facilities. This study looks at survival time and associated factors among adults with HIV in south Gondar, Northwest Ethiopia.

Methods: A 5-year retrospective cohort study design was conducted using patient records among 746 adults living with HIV/AIDS. A systematic random sampling technique was used to select respondents after proportional allocation was made for all health facilities included in the study. Epi-info version 7 and STATA 12 were used for data entry and analysis, respectively. Kaplan-Meier survival analysis was used to estimate mean survival time and a life table was used to estimate survival probability after initiation of HAART.

Results: A total of 746 respondents were followed for a median of 60 months. There were 102 (13.67%) deaths yielding an overall mortality rate of 2.59/1,000-person year observation (95% CI=0.02136-0.031736). Age of respondents >43 years (AHR=2.790; 95% CI=1.495-5.206), bedridden (AHR=9.57; 95% CI=3.87-23.64), past TB treatment (AHR=0.86; 95% CI=0.46-0.609), baseline WHO stage IV (AHR=3.02; 95% CI=1.77-5.18), pneumonia after ART start (AHR=3.6; 95% CI=1.4-9.2), INH prophylaxis (AHR=2.58; 95% CI=1.232-5.188), ambulatory functional status (AHR=5.86; 95% CI=2.67-12.86), and disclosure status (AHR=0.423; 95% CI=0.261-0.685) were significant predictors for survival time after initiation of HAART among adults living with HIV.

Conclusion: The mortality rate was highly (13.67%) observed in the early phase of antiretroviral treatment. Being ambulatory and bedridden, age of respondents >43 years, past TB treatment, baseline WHO stage IV, pneumonia after HAART, INH prophylaxis, and disclosure status were independent predictors of mortality.

Citing Articles

Predictors of survival among older adults with HIV in Uganda's AIDS support organization centers of excellence (1987-2023): a retrospective longitudinal study.

Atuhairwe C, Atuhaire L, Wandera S, Amongin D, Ochieng T, Misinde C AIDS Res Ther. 2025; 22(1):24.

PMID: 40011930 PMC: 11863521. DOI: 10.1186/s12981-024-00687-4.

Exploring survival rates in HIV-infected Ethiopian children receiving HAART: a retrospective cohort study.

Getaneh Y, Dejene Y, Adankie B, Khairunisa S, Husada D, Kuntaman K BMJ Paediatr Open. 2025; 9(1.

PMID: 39824536 PMC: 11749865. DOI: 10.1136/bmjpo-2024-003022.

Survival and predictors of mortality among HIV-infected adults after initiation of antiretroviral therapy in Eastern Ethiopia Governmental hospitals, from January 2015 to December 2021 (multi-center retrospective follow-up study).

Argaw G, Gelaye K, Lakew A, Aragaw F, Chekol Y, Tesfie T BMC Infect Dis. 2024; 24(1):1352.

PMID: 39592986 PMC: 11600927. DOI: 10.1186/s12879-024-10225-2.

Highly active antiretroviral therapy is necessary but not sufficient. A systematic review and meta-analysis of mortality incidence rates and predictors among HIV-infected adults receiving treatment in Ethiopia, a surrogate study for resource-poor....

Woldegeorgis B, Asgedom Y, Habte A, Kassie G, Badacho A BMC Public Health. 2024; 24(1):1735.

PMID: 38943123 PMC: 11214252. DOI: 10.1186/s12889-024-19268-1.

Incidence of Mortality and Its Predictors Among Adult Human Immune Virus Infected Patients on Antiretroviral Therapy in Wolaita Sodo University Comprehensive Specialized Hospital, Southern Ethiopia: A Retrospective Follow-Up Study.

Barata T, Abiso G, Israel E, Molla S, Wolka E HIV AIDS (Auckl). 2023; 15:361-375.

PMID: 37359271 PMC: 10289094. DOI: 10.2147/HIV.S401155.

References

Poka-Mayap V, Pefura-Yone E, Kengne A, Kuaban C . Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study. BMJ Open. 2013; 3(7). PMC: 3710986. DOI: 10.1136/bmjopen-2013-003210. View

Roura M, Busza J, Wringe A, Mbata D, Urassa M, Zaba B . Barriers to sustaining antiretroviral treatment in Kisesa, Tanzania: a follow-up study to understand attrition from the antiretroviral program. AIDS Patient Care STDS. 2009; 23(3):203-10. PMC: 2776987. DOI: 10.1089/apc.2008.0129. View

Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E . Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study. PLoS One. 2015; 10(9):e0136117. PMC: 4560381. DOI: 10.1371/journal.pone.0136117. View

Bhatta L, Klouman E, Deuba K, Shrestha R, Karki D, Ekstrom A . Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in Far-western region, 2006-2011. BMC Infect Dis. 2013; 13:604. PMC: 3880177. DOI: 10.1186/1471-2334-13-604. View

Obi S, Ifebunandu N, Onyebuchi A . Nutritional status of HIV-positive individuals on free HAART treatment in a developing nation. J Infect Dev Ctries. 2011; 4(11):745-9. DOI: 10.3855/jidc.863. View

Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E . Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: a randomized controlled trial. AIDS Behav. 2011; 15(8):1795-802. DOI: 10.1007/s10461-011-9927-9. View

Abebe N, Alemu K, Asfaw T, Abajobir A . Survival status of hiv positive adults on antiretroviral treatment in Debre Markos Referral Hospital, Northwest Ethiopia: retrospective cohort study. Pan Afr Med J. 2014; 17:88. PMC: 4247735. DOI: 10.11604/pamj.2014.17.88.3262. View

Johannessen A, Naman E, Ngowi B, Sandvik L, Matee M, Aglen H . Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008; 8:52. PMC: 2364629. DOI: 10.1186/1471-2334-8-52. View

Alfven T, Erkkola T, Ghys P, Padayachy J, Warner-Smith M, Rugg D . Global AIDS Reporting-2001 to 2015: Lessons for Monitoring the Sustainable Development Goals. AIDS Behav. 2017; 21(Suppl 1):5-14. PMC: 5515967. DOI: 10.1007/s10461-016-1662-9. View

10.

Ayele W, Mulugeta A, Desta A, Rabito F . Treatment outcomes and their determinants in HIV patients on Anti-retroviral Treatment Program in selected health facilities of Kembata and Hadiya zones, Southern Nations, Nationalities and Peoples Region, Ethiopia. BMC Public Health. 2015; 15:826. PMC: 4549910. DOI: 10.1186/s12889-015-2176-5. View

11.

Aziz N, Sokoloff A, Kornak J, Leva N, Mendiola M, Levison J . Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation. BJOG. 2013; 120(12):1534-47. DOI: 10.1111/1471-0528.12226. View

12.

Stangl A, Lloyd J, Brady L, Holland C, Baral S . A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come?. J Int AIDS Soc. 2013; 16(3 Suppl 2):18734. PMC: 3833106. DOI: 10.7448/IAS.16.3.18734. View

13.

Rangarajan S, Donn J, Giang L, Bui D, Hung Nguyen H, Tou P . Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad. 2016; 2(2):94-101. PMC: 4965252. View

14.

Lin K, Cheng C, Li C, Yang C, Tsai M, Liu C . Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One. 2017; 12(6):e0179870. PMC: 5493332. DOI: 10.1371/journal.pone.0179870. View

15.

Gandhi T, Wei W, Amin K, Kazanjian P . Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Clin Infect Dis. 2006; 42(6):878-84. DOI: 10.1086/500210. View

16.

Joseph B, Wood E, Hayashi K, Kerr T, Barrios R, Parashar S . Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. AIDS. 2015; 30(6):925-32. PMC: 4814226. DOI: 10.1097/QAD.0000000000000989. View

17.

Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B . Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224(4648):500-3. DOI: 10.1126/science.6200936. View

18.

Tweya H, Feldacker C, Breeze E, Jahn A, Haddad L, Ben-Smith A . Incidence of pregnancy among women accessing antiretroviral therapy in urban Malawi: a retrospective cohort study. AIDS Behav. 2012; 17(2):471-8. DOI: 10.1007/s10461-012-0150-0. View

19.

Mengesha S, Belayihun B, Kumie A . Predictors of Survival in HIV-Infected Patient after Initiation of HAART in Zewditu Memorial Hospital, Addis Ababa, Ethiopia. Int Sch Res Notices. 2016; 2014:250913. PMC: 4897553. DOI: 10.1155/2014/250913. View